Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience
Conclusions:
One-third of eyes with DME responded well to PRN treatment strategy from the first month without 3 loading doses of ranibizumab. Baseline visual acuity is the best predictor of vision at 1 and 2 years of follow-up.
Source: Asia-Pacific Journal of Ophthalmology - Category: Opthalmology Tags: Original Clinical Study Source Type: research
More News: Diabetes | Endocrinology | Eyes | Lucentis | Opthalmology | Ranibizumab Injection | Study